RxDoctor Payments Data

Brett Johnson, MD

Family Medicine · Dallas, TXNPI 1356327399

Payments from drug & device makers

$1,014in general payments, 2019–2025

Across 18 payments — averaging $56.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tepha Inc$205
  • Boston Scientific$182
  • Davol Inc.$139
  • AbbVie$130
  • Lexicon Pharmaceuticals, Inc.$121
  • Coloplast$84
  • plus $153 from 7 others

What the payments were for

  • Food & beverage$1,014100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,014 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$10,057
Medicare patients
68
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$25,809
OzempicSemaglutide16$23,406
MounjaroTirzepatide19$22,727
FarxigaDapagliflozin Propanediol24$22,320
TrulicityDulaglutide19$18,226
JardianceEmpagliflozin14$14,427
EntrestoSacubitril/Valsartan11$5,036
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$4,595
Humalog Kwikpen U-100Insulin Lispro19$3,030
Omega-3 Acid Ethyl Esters34$1,847
Albuterol Sulfate HfaAlbuterol Sulfate34$1,321
Rosuvastatin Calcium57$1,109
Oxcarbazepine28$952
Atorvastatin Calcium151$935
Gabapentin41$750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$25,80922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →